Vaxxinity aims to disrupt the biologics market with a vaccine platform that replaces mAbs for chronic disease by inducing patients’ immune systems to manufacture therapeutic antibodies in vivo. But...
...activity, deals, drug approvals and clinical development progress,” Medical Strategy GmbH’s Mario Linimeier told BioCentury. E Squared Capital Management’s...
...fourth quarter of ‘18, I think investors are going to be a lot more picky,” E Squared Capital Management’s... ...too short a period of time, the IPO market could die of indigestion.” Les Funtleyder, E Squared Capital Management...
Vaxxinity aims to disrupt the biologics market with a vaccine platform that replaces mAbs for chronic disease by inducing patients’ immune systems to manufacture therapeutic antibodies in vivo. But...
...activity, deals, drug approvals and clinical development progress,” Medical Strategy GmbH’s Mario Linimeier told BioCentury. E Squared Capital Management’s...
...fourth quarter of ‘18, I think investors are going to be a lot more picky,” E Squared Capital Management’s... ...too short a period of time, the IPO market could die of indigestion.” Les Funtleyder, E Squared Capital Management...
